VTVT
vTv Therapeutics Inc.
$34.63
+0.51 (+1.49%)
At close · Jul 8
Market Cap
$136.40M
Shares
3,938,895
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$34.63
Open$34.12
Day$33.65–35.78
52W$14.00–44.00
Avg vol 30d51K
Short int159K · 4.0% float · 4.7d
Short vol81%
Last earningsMay 13, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 13
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+7%
above
Price vs 50-day avg
+3%
above
RSI (14)
50
neutral
MACD trend
Negative
52-week position
69%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+8%
trailing
6-month return
−7%
trailing
YTD return
−13%
this year
Relative strength
−15%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $34 › 200d $32 — 50d above 200d
Institutional flow
Flat
1 of 35 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.02% of float · ▲ +0.8% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
35 holders — near 3-yr high, broad support
Squeeze score
59
elevated · 0–100
Fundamentals
Revenue growth
−100%
Y/Y
Free cash flow
$-25.3M
Balance sheet
$83.9M
net cash
Quant / Vol
risk profile
Volatility
75%
annualized · 1-yr
Max drawdown
−32%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 9, 2026
Est · unconfirmed
· in 4 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 13, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+7%
Bullish
Price vs 50-day avg
+3%
Bullish
RSI (14)
50
Neutral
MACD trend
Negative
Bearish
52-week position
69%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $34 › 200d $32 — 50d above 200d
Institutional flow
Flat
1 of 35 funds reported for Jun 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
4.02% of float · ▲ +0.8% MoM · 4.7 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
35 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $14
Now $35 · 69%
52-wk high $44
vs 200-day avg +7%
vs 50-day avg +3%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
VTVT
this stock
vTv Therapeutics Inc.
|
$136.40M | -13.4% | -100.0% | — | 4.0% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| VTVT | -8.0% | +8.0% | -7.2% | -8.0% | -13.4% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | -7.8% | +7.2% | -14.7% | -7.8% | -22.7% |